2269N Stock Chart & Stats
$66.00
$0.00(0.00%)
At close: 4:00 PM EDT
$66.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$66.00 - $66.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$519.65B
Enterprise Value$140.19B
Total Cash (Recent Filing)$13.04B
Total Debt (Recent Filing)$2.73B
Price to Earnings (P/E)38.6
Beta0.00
Next Earnings
Mar 23, 2027EPS Estimate
1.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.21
Shares Outstanding4,116,330,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)2.49
Price to Sales (P/S)5.41
P/FCF Ratio42.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$134.22Price Target Upside103.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)3.28
Revenue Forecast (FY)$59.38B
Bulls Say, Bears Say
Bulls Say
Healthy ProfitabilityStrong gross, EBIT, and net margins indicate that Wuxi Biologics retains meaningful economics in its biologics CDMO services. This profitability provides internal funding for capacity, technology, and customer support while offering resilience across development and manufacturing projects.
Conservative Balance SheetVery low and improving leverage gives Wuxi Biologics substantial financial flexibility. A sizeable equity base and limited debt burden reduce pressure on operating cash flow, support continued investment in its service platform, and improve resilience if customer activity softens.
Improving Free Cash FlowThe return to positive free cash flow and its strong 2025 increase demonstrate improving cash generation after earlier investment and working-capital volatility. Better cash production can support facility development, operational needs, and growth without relying as heavily on external financing.
Bears Say
Recent Revenue Growth SlowdownAlthough revenue expanded strongly over the longer term, the sharp deceleration in the two latest annual reports signals weaker near-term growth in customer projects or service volumes. Persistently slower expansion could limit operating leverage and reduce the pace of earnings compounding.
Weak Cash ConversionCash generation remains below reported profitability, so earnings are not yet converting fully into discretionary funds. This can constrain the amount available for expansion or shareholder returns and indicates that working capital and investment demands may continue to create cash-flow variability.
Margins Below Prior PeaksCurrent margins remain healthy, but their position below earlier peaks suggests normalization or mix and cost pressure within the service portfolio. If this persists, it could limit incremental profit growth even if revenue continues to expand across biologics development and manufacturing.
Wuxi Biologics (Cayman) News
2269N FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was $66.00 and its highest was $66.00 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Wuxi Biologics (Cayman) Inc.’s market cap is $519.65B.
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Mar 23, 2027 which is in 170 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Aug 25, 2026. The company reported $1.554 earnings per share for the quarter, beating the consensus estimate of $1.206 by $0.348.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is 1.94.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,116,330,600 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of $1.554 in its last earnings report, beating expectations of $1.206. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Currently, no hedge funds are holding shares in MX:2269N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Wuxi Biologics (Cayman) Inc.
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
2269N Company Deck
2269N Earnings Call
Q2 2026
0:00 / 0:00
2269N Stock 12 Month Forecast
Average Price Target
$134.22
▲(103.36% Upside)